Accessibility Menu
Amplia Therapeutics logo

Amplia Therapeutics(OTC) INNMF

Market Cap$56.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-30%
5 Year-5%
1 Year-8%
1 Month+15%
$0.11
+4.09%
+0.00Today
Amplia Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.112026-08-17
Amplia Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+14.5%USD 0.102026-08-10
1 month+14.5%USD 0.102026-07-17
3 month+1.51%USD 0.112026-05-19
Year to date+45.12%USD 0.082025-12-30
1 year-8.4%USD 0.132025-08-14
3 year+129%USD 0.052023-08-18
5 year-5.37%USD 0.122021-08-18
Since inception-29.94%USD 0.162016-01-11

Amplia Therapeutics Financials at a Glance

Market Cap

$56.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$3.78M

Net Income (TTM)

-A$14.11M

EPS (TTM)

-$0.01

P/E Ratio

-10.00

Dividend

$0.00

Beta (Volatility)

0.52 (Low)

Price

$0.11

Volume

215,555

Open

$0.07

Previous Close

$0.11

Daily Range

$0.07 - $0.12

52-Week Range

$0.05 - $0.27

Estimated Earnings Date

Nov 27, 2026

INNMF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Amplia Therapeutics

Amplia Therapeutics Limited is a biotechnology company based in Melbourne, Australia, focused on developing innovative therapies targeting cancer and chronic fibrotic diseases. The company specializes in focal adhesion kinase (FAK) inhibitors, with a promising pipeline that includes AMP945 and AMP886.

Products and Services
  • AMP945: A FAK inhibitor in Phase I trials for pancreatic cancer and fibrotic diseases
  • AMP886: Another FAK inhibitor under development for cancer and fibrotic disorders
  • Strategic collaboration with the Garvan Institute of Medical Research for advanced research
Growth Outlook
  • Successful Phase I trials for AMP945 indicate potential for future clinical advancements
  • Focus on oncology and fibrotic diseases aligns with growing market demand
  • Strong cash position supports ongoing research and development initiatives
Financial Highlights
  • Recent quarterly revenue of 0, reflecting ongoing investment in R&D
  • Cash and cash equivalents of approximately AUD 27.9 million as of March 2026
  • Current ratio of 19.78 indicates strong liquidity and financial health
Amplia Therapeutics Limited is positioned in a dynamic sector with significant growth potential. The company's focus on FAK inhibitors addresses critical unmet needs in oncology and fibrotic diseases, which are areas of increasing interest in the pharmaceutical industry. The successful completion of Phase I trials for AMP945 is a notable milestone, suggesting that the company is on a promising path toward further clinical development. With a robust cash position, Amplia is well-equipped to continue its research and development efforts, potentially leading to significant advancements in treatment options for patients.
AI Generated • Aug 12, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Christopher J. Burns, PhD

Website

www.ampliatx.com

Headquarters

Melbourne, VIC 3000, AU

INNMF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-18.71%

Return on Capital

-33.10%

Return on Assets

-18.60%

Earnings Yield

-10.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$56.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

513.31M

Volume

215.56K

Avg. Volume

24.74K

Financials (TTM)

Gross Profit

A$3.48M

Operating Income

-A$19.70M

EBITDA

-A$19.80M

Operating Cash Flow

-A$15.97M

Capital Expenditure

-A$35.39K

Free Cash Flow

-A$15.98M

Cash & ST Invst.

A$27.91M

Total Debt

A$341.75K

Amplia Therapeutics Performance Analysis

Amplia Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31AUD 0N/A
20242024-03-31AUD 0N/A
20252025-03-31AUD 0N/A
20262026-03-31AUD 0N/A
Amplia Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-09-30-29.8%
Q42025-03-3168.9%
Q22025-09-30-100.0%
Q42026-03-31N/A
Amplia Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31AUD -0.0219.3%
20242024-03-31AUD -0.01-31.0%
20252025-03-31AUD -0.01-4.1%
20262026-03-31AUD -0.01-22.3%
Amplia Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-09-3036.2%
Q42025-03-316.3%
Q22025-09-305.8%
Q42026-03-3128.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$55.95K

-103.3%

Gross Margin

0.00%

N/A

Market Cap

$56.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$56.46M

N/A

Employees

1

N/A

Net Income

-A$3.54M

-4.8%

EBITDA

-A$6.13M

-82.1%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$27.91M

+724.3%

Total Debt

A$341.75K

-78.5%

Accounts Receivable

A$4.79M

+50.7%

Inventory

A$0.00

N/A

Long Term Debt

A$252.34K

+1716.3%

Short Term Debt

A$89.42K

-94.3%

Return on Assets

-18.60%

N/A

Return on Invested Capital

-33.14%

N/A

Free Cash Flow

-A$1.10M

+31.0%

Operating Cash Flow

-A$1.09M

+31.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ACHFFArch Biopartners Inc.
$0.76-7.62%
CVALFCovalon Technologies Ltd.
$1.69+0.00%
OTLCOncotelic Therapeutics, Inc.
$0.04-5.05%
ZIVOZIVO Bioscience, Inc.
$4.05-5.62%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.61-0.02%
SPCXSpace Exploration Technologies
$146.23+0.04%
IPSTIp Strategy
$7.39+2.36%
NVDANvidia
$225.01-0.00%

Questions About INNMF

What is the current price of Amplia Therapeutics?

Amplia Therapeutics is trading at $0.11 per share.

What is the 52-week range for Amplia Therapeutics?

Over the past 52 weeks, Amplia Therapeutics has traded between $0.05 and $0.27.

How much debt does Amplia Therapeutics have?

As of the most recent reporting period, Amplia Therapeutics reported total debt of A$233.63K.

How much cash does Amplia Therapeutics have on hand?

Amplia Therapeutics reported A$19.08M in cash and cash equivalents in its most recent financial results.

What is Amplia Therapeutics’s dividend yield?

Amplia Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services